Hila Karah
Known title: DirectorCIK: 0001668116
Associated companies
Transaction History
| DRIO | ▲ Buy | Grant | 28,000 | $0 | 9/24/2026 | View on chart |
| DRIO | ▲ Buy | Grant | 20,000 | $0 | 9/11/2025 | View on chart |
| DRIO | ▲ Buy | Grant | 70,000 | $0 | 3/6/2024 | View on chart |
| DRIO | ▲ Buy | Grant | 80,000 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction
DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction. DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.